about
Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: results of the ALFA-0701 trial.NUP214-ABL1 fusion defines a rare subtype of B-cell precursor acute lymphoblastic leukemia that could benefit from tyrosine kinase inhibitorsTetraspanin CD81 is an adverse prognostic marker in acute myeloid leukemia.Linezolid induces ring sideroblasts.Quantification of JAK2V617F mutation by next-generation sequencing technology.Detection of a new heterozygous germline ETV6 mutation in a case with hyperdiploid acute lymphoblastic leukemia.Acquisition of genomic events leading to lymphoblastic transformation in a rare case of myeloproliferative neoplasm with BCR-JAK2 fusion transcript.CD9 in acute myeloid leukemia: Prognostic role and usefulness to target leukemic stem cellsParoxysmal nocturnal hemoglobinuria (PNH) and T cell large granular lymphocyte (LGL) leukemia--an unusual association: another cause of cytopenia in PNHBone marrow necrosis: a culture medium for bacteria[Renal extramedullary hematopoietic tumor revealing a hereditary spherocytosis in an adult patient]Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow UpMolecular characteristics of multifocal brain histiocytic sarcomat(6;9)(p23;q34.1) acute myeloid leukaemia with cup-like blastsImpact of Wilms' tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AMLInherited transmission of the CSF3R T618I mutational hotspot in familial chronic neutrophilic leukemiaRelapse of multiple myeloma presenting as pericardial effusionFamilial myeloid malignancies with germline TET2 mutationDisease escape with the selective loss of the Philadelphia chromosome after tyrosine kinase inhibitor exposure in Ph-positive acute lymphoblastic leukemiaImmature platelet fraction (IPF): A reliable tool to predict peripheral thrombocytopenia
P50
Q33572303-5EF3DCB7-52EC-4C45-ACC7-E4B1151DCE15Q37216300-964C6BF5-24EA-4040-862F-B465802B989FQ37641783-BF96F89F-EDD7-4F85-A0A3-D7479EA12BA9Q42924725-1F21712D-F909-4933-BC98-03146461E4CDQ44186784-7D67A164-8F81-4971-A999-81DD5A250FE5Q48184463-0305C06D-8EC3-4DCF-A70A-B5FF6EC44BE7Q54210991-6B9C2947-1599-4560-84EF-8CE970AD3A47Q64279981-608C02EB-D2B1-4F02-ADF8-F30D8D9F4DD6Q85552142-8A6E50AF-0777-4047-A66A-679C47C00A05Q86880447-9B992961-B86D-464C-A530-66344C820D0AQ86968755-1A89294B-BDA5-4BF9-A170-EBDE52F6719EQ88305968-6FBD225A-C5EE-4C6A-8231-13CAE3BA82EBQ88428438-3B611A3C-C358-4E5F-9A36-3A73E87F5D0AQ88691074-6C0CA6CB-422D-4E8A-AD71-795B25BF3388Q89483800-2D6C4709-F3CF-4822-B949-299AAF615A7EQ91165027-DC8B209B-E1A7-47EE-AF2D-39BA1D25EE30Q91408736-3A19EE06-3D10-4202-95F2-6D1B291DAE40Q91892264-2BC76B8C-4B65-46A9-887D-08D2398D3BF8Q92978956-14DBDBE4-765B-4A02-8238-012315F38F43Q93108785-86017CC7-F2D4-4C0D-A3E6-716F1701C0CA
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0001-8133-5491
@en
name
Thomas Boyer
@ast
Thomas Boyer
@en
Thomas Boyer
@es
Thomas Boyer
@nl
type
label
Thomas Boyer
@ast
Thomas Boyer
@en
Thomas Boyer
@es
Thomas Boyer
@nl
prefLabel
Thomas Boyer
@ast
Thomas Boyer
@en
Thomas Boyer
@es
Thomas Boyer
@nl
P106
P31
P496
0000-0001-8133-5491